You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Through the public-private consortium of companies and institutions across Asia and Austria, the company aims to advance biomarker-driven cancer research.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
The alliance will join Sanofi's oncology pipeline with MD Anderson's premier clinical trials infrastructure to identify new biomarkers and streamline patient selection.
Both drugs are being investigated in cancer patients harboring biomarkers detected by the company's drug response predictor platform.
The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.
The study will evaluate the safety, tolerability and clinical activity of JSI-1187 in patients with relapsed, refractory solid tumors containing mutations in the MAPK pathway.
The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.
The approval will make Merck and AstraZeneca's Lynparza available to patients in the EU who have not progressed after 16 weeks on platinum-based chemotherapy.